A phase I, multi-dose study of SGN-33 (anti-huCD33 mAb; HuM195; lintuzumab) in patients with acute myeloid leukaemia and myelodysplastic syndrome

Trial Profile

A phase I, multi-dose study of SGN-33 (anti-huCD33 mAb; HuM195; lintuzumab) in patients with acute myeloid leukaemia and myelodysplastic syndrome

Completed
Phase of Trial: Phase I

Latest Information Update: 31 Dec 2014

At a glance

  • Drugs Lintuzumab (Primary)
  • Indications Acute myeloid leukaemia; Myelodysplastic syndromes
  • Focus Adverse reactions; Pharmacokinetics; Therapeutic Use
  • Sponsors Seattle Genetics
  • Most Recent Events

    • 31 Dec 2014 Last checked against ClinicalTrials.gov record.
    • 24 Aug 2010 Actual end date (Jan 2010) added as reported by ClinicalTrials.gov.
    • 09 Jun 2009 Status changed from active, no longer recruiting to completed, according to a Seattle Genetics media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top